Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark.
Pedersen KBH, Knudsen A, Møller S, Siebner HR, Hove JD, Gerstoft J, Benfield T. Pedersen KBH, et al. BMJ Open. 2023 Aug 21;13(8):e075673. doi: 10.1136/bmjopen-2023-075673. BMJ Open. 2023. PMID: 37604629 Free PMC article. Clinical Trial.
A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia.
Thorlacius-Ussing L, Brooks PT, Nielsen H, Jensen BA, Wiese L, Sækmose SG, Johnsen S, Gybel-Brask M, Johansen IS, Bruun MT, Stærke NB, Østergaard L, Erikstrup C, Ostrowski SR, Homburg KM, Georgsen J, Mikkelsen S, Sandholdt H, Leding C, Hovmand N, Clausen CL, Tinggaard M, Pedersen KBH, Iversen KK, Tingsgård S, Israelsen SB, Benfield T. Thorlacius-Ussing L, et al. Among authors: pedersen kbh. Sci Rep. 2022 Sep 30;12(1):16385. doi: 10.1038/s41598-022-19629-z. Sci Rep. 2022. PMID: 36180450 Free PMC article. Clinical Trial.
DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.
Madurka I, Vishnevsky A, Soriano JB, Gans SJ, Ore DJS, Rendon A, Ulrik CS, Bhatnagar S, Krishnamurthy S, Mc Harry K, Welte T, Fernandez AA, Mehes B, Meiser K, Gatlik E, Sommer U, Junge G, Rezende E; Study group. Madurka I, et al. Infection. 2023 Jun;51(3):641-654. doi: 10.1007/s15010-022-01904-w. Epub 2022 Sep 14. Infection. 2023. PMID: 36104613 Free PMC article. Clinical Trial.
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial.
Gunst JD, Højen JF, Pahus MH, Rosás-Umbert M, Stiksrud B, McMahon JH, Denton PW, Nielsen H, Johansen IS, Benfield T, Leth S, Gerstoft J, Østergaard L, Schleimann MH, Olesen R, Støvring H, Vibholm L, Weis N, Dyrhol-Riise AM, Pedersen KBH, Lau JSY, Copertino DC Jr, Linden N, Huynh TT, Ramos V, Jones RB, Lewin SR, Tolstrup M, Rasmussen TA, Nussenzweig MC, Caskey M, Reikvam DH, Søgaard OS. Gunst JD, et al. Among authors: pedersen kbh. Nat Med. 2023 Oct;29(10):2547-2558. doi: 10.1038/s41591-023-02547-6. Epub 2023 Sep 11. Nat Med. 2023. PMID: 37696935 Free PMC article. Clinical Trial.